Defence Therapeutics Expands Patent Portfolio Globally

Defence Therapeutics Inc., a Canadian biopharmaceutical company, recently announced the issuance of several new patents and allowances of patent applications, underlining its expanding global patent protection for its innovative technologies in immune-oncology vaccines and drug delivery systems. Significant advancements include the U.S. Patent Office's recent approval of an application broadly covering the company’s Accum® technology, pivotal for enhancing antigen presentation in vaccines.

In addition to its success in the U.S., Defence has achieved milestone patent grants in international markets including Australia and Japan. The Australian patent solidifies Defence's capabilities in developing antibody-drug conjugates with their original Accum® technology, vital for targeted cellular delivery in cancer treatment. Meanwhile, Japan and Canada have recognized Defence’s unique method of improving vaccines by covalently bonding antigens to variants of Accum®.

CEO Sebastien Plouffe expressed enthusiasm about these achievements, underscoring their importance in enhancing global healthcare through innovative therapeutic strategies. The company is also currently speeding up the examination of remaining applications, aiming for rapid approvals to further strengthen its patent network and support upcoming clinical trials.